Cargando…
Identification immune response genes in psoriasis after treatment with secukinumab
BACKGROUND: Secukinumab is a fully human IgG1κ MoAb that selectively binds to IL-17A with high affinity, and it has been proven effective for the treatment of psoriasis. However, the immune response pathways and mechanisms during the treatment are still masked. Therefore, the current study was desig...
Autores principales: | Wang, Jing, Liu, Yufang, Zhang, Yuxin, Wang, Shiyan, Kang, Shaomei, Mi, Ningyu, Li, Ruxin, Zou, Yulin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082531/ https://www.ncbi.nlm.nih.gov/pubmed/37029373 http://dx.doi.org/10.1186/s12920-023-01507-w |
Ejemplares similares
-
Literature Overview of the Relation Between Psoriasis and Alzheimer
por: Yang, Qian, et al.
Publicado: (2023) -
Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018) -
Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016) -
Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023) -
Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)